This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Geschwind, J.-F. H. Articles by Pedersen, P. L. Search for Related Content PubMed PubMed Citation Articles by Geschwind, J.-F. H. Articles by Pedersen, P. L.

Novel Therapy for Liver Cancer

Direct Intraarterial Injection of a Potent Inhibitor of ATP Production¹

Division of Cardiovascular and Interventional Radiology, The Russell H. Morgan Department of Radiology [J-F. H. G., C. M.], Department of Biological Chemistry [Y. H. K., P. L. P.], and Department of Pathology [M. S. T.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2185

Most types of cancer are difficult to eradicate and some, like liver carcinomas, are almost always fatal. Significantly, we report here that direct intraarterial delivery of 3-bromopyruvate (3-BrPA), a potent inhibitorof cell ATP production, to liver-implanted rabbit tumors, inflicts a rapid, lethal blow to most cancer cells therein. Moreover, systemic delivery of 3-BrPA suppresses "metastatic" tumors that arise in the lungs. In both cases, there is no apparent harm to other organs or to the animals. Thus, intraarterial delivery of agents like 3-BrPA directly to the site of the primary tumor, followed by systemic delivery only when necessary, may represent a powerful new strategy for arresting the growth of liver and other cancers while minimizing toxic side effects.

This article has been cited by other articles:

				G. Filomeni, S. Piccirillo, I. Graziani, S. Cardaci, A. M. Da Costa Ferreira, G. Rotilio, and M. R. Ciriolo The isatin-Schiff base copper(II) complex Cu(isaepy)2 acts as delocalized lipophilic cation, yields widespread mitochondrial oxidative damage and induces AMP-activated protein kinase-dependent apoptosis Carcinogenesis, July 1, 2009; 30(7): 1115 - 1124. [Abstract] [Full Text] [PDF]

				J P. Couto, H Prazeres, P Castro, J Lima, V Maximo, P Soares, and M Sobrinho-Simoes How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer J. Clin. Pathol., May 1, 2009; 62(5): 414 - 421. [Abstract] [Full Text] [PDF]

				X. ZHANG, E. VARIN, S. ALLOUCHE, Y. LU, L. POULAIN, and P. ICARD Effect of Citrate on Malignant Pleural Mesothelioma Cells: A Synergistic Effect with Cisplatin Anticancer Res, April 1, 2009; 29(4): 1249 - 1254. [Abstract] [Full Text] [PDF]

				X. ZHANG, E. VARIN, M. BRIAND, S. ALLOUCHE, N. HEUTTE, L. SCHWARTZ, L. POULAIN, and P. ICARD Novel Therapy for Malignant Pleural Mesothelioma Based on Anti-energetic Effect: An Experimental Study Using 3-Bromopyruvate on Nude Mice Anticancer Res, April 1, 2009; 29(4): 1443 - 1448. [Abstract] [Full Text] [PDF]

				L.-F. Dong, R. Freeman, J. Liu, R. Zobalova, A. Marin-Hernandez, M. Stantic, J. Rohlena, K. Valis, S. Rodriguez-Enriquez, B. Butcher, et al. Suppression of Tumor Growth In vivo by the Mitocan {alpha}-tocopheryl Succinate Requires Respiratory Complex II Clin. Cancer Res., March 1, 2009; 15(5): 1593 - 1600. [Abstract] [Full Text] [PDF]

				L. Arzoine, N. Zilberberg, R. Ben-Romano, and V. Shoshan-Barmatz Voltage-dependent Anion Channel 1-based Peptides Interact with Hexokinase to Prevent Its Anti-apoptotic Activity J. Biol. Chem., February 6, 2009; 284(6): 3946 - 3955. [Abstract] [Full Text] [PDF]

				M. Vali, J. A. Vossen, M. Buijs, J. M. Engles, E. Liapi, V. P. Ventura, A. Khwaja, O. Acha-Ngwodo, G. Shanmugasundaram, L. Syed, et al. Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 32 - 37. [Abstract] [Full Text] [PDF]

				D. J. Wong, D. S.A. Nuyten, A. Regev, M. Lin, A. S. Adler, E. Segal, M. J. van de Vijver, and H. Y. Chang Revealing Targeted Therapy for Human Cancer by Gene Module Maps Cancer Res., January 15, 2008; 68(2): 369 - 378. [Abstract] [Full Text] [PDF]

				W. Kim, J.-H. Yoon, J.-M. Jeong, G.-J. Cheon, T.-S. Lee, J.-I. Yang, S.-C. Park, and H.-S. Lee Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma Mol. Cancer Ther., September 1, 2007; 6(9): 2554 - 2562. [Abstract] [Full Text] [PDF]

				J. Neuzil, M. Tomasetti, Y. Zhao, L.-F. Dong, M. Birringer, X.-F. Wang, P. Low, K. Wu, B. A. Salvatore, and S. J. Ralph Vitamin E Analogs, a Novel Group of "Mitocans," as Anticancer Agents: The Importance of Being Redox-Silent Mol. Pharmacol., May 1, 2007; 71(5): 1185 - 1199. [Abstract] [Full Text] [PDF]

				M. I. Koukourakis, A. Giatromanolaki, A. L. Harris, and E. Sivridis Comparison of Metabolic Pathways between Cancer Cells and Stromal Cells in Colorectal Carcinomas: a Metabolic Survival Role for Tumor-Associated Stroma Cancer Res., January 15, 2006; 66(2): 632 - 637. [Abstract] [Full Text] [PDF]

				A. Isidoro, E. Casado, A. Redondo, P. Acebo, E. Espinosa, A. M. Alonso, P. Cejas, D. Hardisson, J. A. Fresno Vara, C. Belda-Iniesta, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis Carcinogenesis, December 1, 2005; 26(12): 2095 - 2104. [Abstract] [Full Text] [PDF]

				R.-h. Xu, H. Pelicano, Y. Zhou, J. S. Carew, L. Feng, K. N. Bhalla, M. J. Keating, and P. Huang Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia Cancer Res., January 15, 2005; 65(2): 613 - 621. [Abstract] [Full Text] [PDF]

				S. Gottschalk, N. Anderson, C. Hainz, S. G. Eckhardt, and N. J. Serkova Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells Clin. Cancer Res., October 1, 2004; 10(19): 6661 - 6668. [Abstract] [Full Text] [PDF]